Havana, May 9 (RHC-PL) -- The final results of the study confirming the effectiveness of CIMAvax-EGF in advanced lung cancer will be presented at an international workshop to be held in Havana on May 12th and 13th.
The implementation of the vaccine, conceived by experts of the Center for Molecular Immunology (CMI), in primary health care, the overall safety profile, post-registration experience in other countries, will also be discussed at the Fifth International Workshop on the subject, which will be held in the Palace of Conventions in Havana.
The event, organized by CIMAB SA, the Cuban biopharmaceutical company dedicated to the development and commercialization of drugs for the treatment of malignant tumors, will aim to discuss new indications and therapeutic combinations of the compound.
CIMAvax-EGF is the first therapeutic vaccine registered for lung cancer, considered a novel approach capable of generating the patient's own antibodies against epidermal growth factor (EGF).
The antibodies generated stop the proliferation of tumor cells, consequently control disease progression, increase survival and improve the quality of life of treated patients.
- Jazz Place
- RHC's national and international news
- UNESCO's Director-General launches COVID-19 Global Education Coalition
- Covid-19: US unpreparedness is rooted in historic ideological tendencies
- RHC's Caribbean Outlook Show
- Visit Cuba
- Max: 19729
- yesterday: 7035
- today: 4858
- online: 185
- total: 7604840